Literature DB >> 34788083

Pathogenesis of Wild-Type-Like Rhesus Cytomegalovirus Strains following Oral Exposure of Immune-Competent Rhesus Macaques.

Yujuan Yue1, W L William Chang1, Julia Li2, Nancy Nguyen1, Kimberli A Schmidt1, Philip R Dormitzer2, Xinzhen Yang2, Peter A Barry1,3,4.   

Abstract

Rhesus cytomegalovirus (RhCMV) infection of rhesus macaques (Macaca mulatta) is a valuable nonhuman primate model of human CMV (HCMV) persistence and pathogenesis. In vivo studies predominantly use tissue culture-adapted variants of RhCMV that contain multiple genetic mutations compared to wild-type (WT) RhCMV. In many studies, animals have been inoculated by nonnatural routes (e.g., subcutaneous, intravenous) that do not recapitulate disease progression via the normative route of mucosal exposure. Accordingly, the natural history of RhCMV would be more accurately reproduced by infecting macaques with strains of RhCMV that reflect the WT genome using natural routes of mucosal transmission. Here, we tested two WT-like RhCMV strains, UCD52 and UCD59, and demonstrated that systemic infection and frequent, high-titer viral shedding in bodily fluids occurred following oral inoculation. RhCMV disseminated to a broad range of tissues, including the central nervous system and reproductive organs. Commonly infected tissues included the thymus, spleen, lymph nodes, kidneys, bladder, and salivary glands. Histological examination revealed prominent nodular hyperplasia in spleens and variable levels of lymphoid lymphofollicular hyperplasia in lymph nodes. One of six inoculated animals had limited viral dissemination and shedding, with commensurately weak antibody responses to RhCMV antigens. These data suggest that long-term RhCMV infection parameters might be restricted by local innate factors and/or de novo host immune responses in a minority of primary infections. Together, we have established an oral RhCMV infection model that mimics natural HCMV infection. The virological and immunological parameters characterized in this study will greatly inform HCMV vaccine designs for human immunization. IMPORTANCE Human cytomegalovirus (HCMV) is globally ubiquitous with high seroprevalence rates in all communities. HCMV infections can occur vertically following mother-to-fetus transmission across the placenta and horizontally following shedding of virus in bodily fluids in HCMV-infected hosts and subsequent exposure of susceptible individuals to virus-laden fluids. Intrauterine HCMV has long been recognized as an infectious threat to fetal growth and development. Since vertical HCMV infections occur following horizontal HCMV transmission to the pregnant mother, the nonhuman primate model of HCMV pathogenesis was used to characterize the virological and immunological parameters of infection following primary mucosal exposures to rhesus cytomegalovirus.

Entities:  

Keywords:  cytomegalovirus; mucosal pathogens; nonhuman primate; rhesus; shedding; viral immunity; viral pathogenesis

Mesh:

Substances:

Year:  2021        PMID: 34788083      PMCID: PMC8826908          DOI: 10.1128/JVI.01653-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  108 in total

1.  Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity.

Authors:  Suzanne P M Welten; Anke Redeker; René E M Toes; Ramon Arens
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 2.  Protein database searches using compositionally adjusted substitution matrices.

Authors:  Stephen F Altschul; John C Wootton; E Michael Gertz; Richa Agarwala; Aleksandr Morgulis; Alejandro A Schäffer; Yi-Kuo Yu
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

3.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

Authors:  S D Elek; H Stern
Journal:  Lancet       Date:  1974-01-05       Impact factor: 79.321

5.  Characterizing human cytomegalovirus reinfection in congenitally infected infants: an evolutionary perspective.

Authors:  Cornelia Pokalyuk; Nicholas Renzette; Kristen K Irwin; Susanne P Pfeifer; Laura Gibson; William J Britt; Aparecida Y Yamamoto; Marisa M Mussi-Pinhata; Timothy F Kowalik; Jeffrey D Jensen
Journal:  Mol Ecol       Date:  2017-02-08       Impact factor: 6.185

6.  Cytomegalovirus excretion in children attending day-care centers.

Authors:  Daniel E Noyola; Beatriz H Valdez-López; Alba E Hernández-Salinas; Miguel A Santos-Díaz; Miguel A Noyola-Frías; Juan F Reyes-Macías; Leticia G Martínez-Martínez
Journal:  Arch Med Res       Date:  2005 Sep-Oct       Impact factor: 2.235

7.  The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains.

Authors:  Yujuan Yue; Amitinder Kaur; Anders Lilja; Don J Diamond; Mark R Walter; Peter A Barry
Journal:  J Gen Virol       Date:  2016-03-14       Impact factor: 3.891

8.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.

Authors:  Kristina Abel; Lisa Strelow; Yujuan Yue; Meghan K Eberhardt; Kimberli A Schmidt; Peter A Barry
Journal:  Vaccine       Date:  2008-08-27       Impact factor: 3.641

9.  Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types.

Authors:  Anders E Lilja; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

10.  Repeated measures study of weekly and daily cytomegalovirus shedding patterns in saliva and urine of healthy cytomegalovirus-seropositive children.

Authors:  Michael J Cannon; Jennifer D Stowell; Rebekah Clark; Philip R Dollard; Delaney Johnson; Karen Mask; Cynthia Stover; Karen Wu; Minal Amin; Will Hendley; Jing Guo; D Scott Schmid; Sheila C Dollard
Journal:  BMC Infect Dis       Date:  2014-11-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.